JP2003504069A - ヒト顆粒球コロニー刺激因子修飾体およびその生産方法 - Google Patents
ヒト顆粒球コロニー刺激因子修飾体およびその生産方法Info
- Publication number
- JP2003504069A JP2003504069A JP2001509533A JP2001509533A JP2003504069A JP 2003504069 A JP2003504069 A JP 2003504069A JP 2001509533 A JP2001509533 A JP 2001509533A JP 2001509533 A JP2001509533 A JP 2001509533A JP 2003504069 A JP2003504069 A JP 2003504069A
- Authority
- JP
- Japan
- Prior art keywords
- csf
- coli
- modified
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 title claims abstract description 155
- 238000004519 manufacturing process Methods 0.000 title claims description 41
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 74
- 150000001413 amino acids Chemical class 0.000 claims abstract description 65
- 244000005700 microbiome Species 0.000 claims abstract description 30
- 239000013604 expression vector Substances 0.000 claims abstract description 22
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 5
- 238000012258 culturing Methods 0.000 claims abstract description 4
- 241000588724 Escherichia coli Species 0.000 claims description 71
- 235000001014 amino acid Nutrition 0.000 claims description 58
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 claims description 42
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 41
- 108020004414 DNA Proteins 0.000 claims description 30
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 claims description 21
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 17
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 16
- 101710146739 Enterotoxin Proteins 0.000 claims description 13
- 239000000147 enterotoxin Substances 0.000 claims description 13
- 231100000655 enterotoxin Toxicity 0.000 claims description 13
- 230000003248 secreting effect Effects 0.000 claims description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 9
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 8
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 8
- 229930182817 methionine Natural products 0.000 claims description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Chemical group CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 6
- 239000004473 Threonine Chemical group 0.000 claims description 6
- 239000004474 valine Substances 0.000 claims description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- 239000004471 Glycine Chemical group 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 210000001322 periplasm Anatomy 0.000 claims description 3
- 108090000204 Dipeptidase 1 Proteins 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 102000006635 beta-lactamase Human genes 0.000 claims description 2
- 108010067006 heat stable toxin (E coli) Proteins 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 101900147372 Escherichia coli Beta-lactamase Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 11
- 210000000805 cytoplasm Anatomy 0.000 abstract description 6
- 239000013598 vector Substances 0.000 description 85
- 239000013612 plasmid Substances 0.000 description 39
- 238000000034 method Methods 0.000 description 28
- 108020004705 Codon Proteins 0.000 description 24
- 108091008146 restriction endonucleases Proteins 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 230000000295 complement effect Effects 0.000 description 16
- 239000012634 fragment Substances 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 230000000692 anti-sense effect Effects 0.000 description 12
- 230000008520 organization Effects 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 10
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 9
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 8
- 230000001086 cytosolic effect Effects 0.000 description 7
- 210000003714 granulocyte Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 6
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 5
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 5
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 108020005038 Terminator Codon Proteins 0.000 description 4
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108700042769 prolyl-leucyl-glycine Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- FXGIMYRVJJEIIM-UWVGGRQHSA-N Pro-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FXGIMYRVJJEIIM-UWVGGRQHSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 101001062854 Rattus norvegicus Fatty acid-binding protein 5 Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102220201851 rs143406017 Human genes 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- QOIGKCBMXUCDQU-KDXUFGMBSA-N Ala-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C)N)O QOIGKCBMXUCDQU-KDXUFGMBSA-N 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- PDQBXRSOSCTGKY-ACZMJKKPSA-N Asn-Ala-Gln Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N PDQBXRSOSCTGKY-ACZMJKKPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100033779 Collagen alpha-4(IV) chain Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101100321669 Fagopyrum esculentum FA02 gene Proteins 0.000 description 1
- 101100321670 Fagopyrum esculentum FA18 gene Proteins 0.000 description 1
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 description 1
- 101000710870 Homo sapiens Collagen alpha-4(IV) chain Proteins 0.000 description 1
- 101100283445 Homo sapiens GNA11 gene Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- PKVZBNCYEICAQP-UHFFFAOYSA-N Mecamylamine hydrochloride Chemical compound Cl.C1CC2C(C)(C)C(NC)(C)C1C2 PKVZBNCYEICAQP-UHFFFAOYSA-N 0.000 description 1
- HAQLBBVZAGMESV-IHRRRGAJSA-N Met-Lys-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O HAQLBBVZAGMESV-IHRRRGAJSA-N 0.000 description 1
- 101100261242 Mus musculus Trdmt1 gene Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 101150080862 NA gene Proteins 0.000 description 1
- 108010065395 Neuropep-1 Proteins 0.000 description 1
- 229930182473 O-glycoside Natural products 0.000 description 1
- 150000008444 O-glycosides Chemical class 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- XQLBWXHVZVBNJM-FXQIFTODSA-N Pro-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 XQLBWXHVZVBNJM-FXQIFTODSA-N 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- SWIKDOUVROTZCW-GCJQMDKQSA-N Thr-Asn-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C)C(=O)O)N)O SWIKDOUVROTZCW-GCJQMDKQSA-N 0.000 description 1
- XOWKUMFHEZLKLT-CIQUZCHMSA-N Thr-Ile-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O XOWKUMFHEZLKLT-CIQUZCHMSA-N 0.000 description 1
- GUHLYMZJVXUIPO-RCWTZXSCSA-N Thr-Met-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O GUHLYMZJVXUIPO-RCWTZXSCSA-N 0.000 description 1
- NOXKHHXSHQFSGJ-FQPOAREZSA-N Tyr-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NOXKHHXSHQFSGJ-FQPOAREZSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 108010045350 alanyl-tyrosyl-alanine Proteins 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019990027418A KR100356140B1 (ko) | 1999-07-08 | 1999-07-08 | 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법 |
| KR1999/27418 | 1999-07-08 | ||
| PCT/KR2000/000733 WO2001004329A1 (en) | 1999-07-08 | 2000-07-07 | Modified human granulocyte-colony stimulating factor and process for producing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003504069A true JP2003504069A (ja) | 2003-02-04 |
| JP2003504069A5 JP2003504069A5 (https=) | 2005-12-22 |
Family
ID=36129291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001509533A Pending JP2003504069A (ja) | 1999-07-08 | 2000-07-07 | ヒト顆粒球コロニー刺激因子修飾体およびその生産方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20040224393A1 (https=) |
| EP (1) | EP1194575B2 (https=) |
| JP (1) | JP2003504069A (https=) |
| KR (1) | KR100356140B1 (https=) |
| CN (1) | CN1195859C (https=) |
| AT (1) | ATE299187T1 (https=) |
| AU (1) | AU757147C (https=) |
| BR (2) | BR0012265A (https=) |
| CA (1) | CA2378543C (https=) |
| DE (1) | DE60021188T3 (https=) |
| DK (1) | DK1194575T4 (https=) |
| ES (1) | ES2243275T5 (https=) |
| NZ (1) | NZ516476A (https=) |
| PT (1) | PT1194575E (https=) |
| RU (1) | RU2232772C2 (https=) |
| WO (1) | WO2001004329A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013540809A (ja) * | 2010-10-29 | 2013-11-07 | ハンミ サイエンス カンパニー リミテッド | 組み換え大腸菌からヒト顆粒球コロニー刺激因子を精製する方法 |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6831158B2 (en) | 2000-01-10 | 2004-12-14 | Maxygen Holdings Ltd. | G-CSF conjugates |
| PL371781A1 (en) | 2001-07-11 | 2005-06-27 | Maxygen Holdings, Ltd. | G-csf conjugates |
| DE60332358D1 (de) * | 2002-09-09 | 2010-06-10 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
| US20090226397A1 (en) | 2003-10-24 | 2009-09-10 | Nora Therapeutics, Inc. | Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination |
| US8338373B2 (en) * | 2003-10-24 | 2012-12-25 | Nora Therapeutics, Inc. | Method for reducing the risk of spontaneous abortion in a human female subject |
| EP2441465B1 (en) | 2003-10-24 | 2014-01-15 | Nora Therapeutics, Inc. | Compositions and methods for healthy pregnancy |
| EP1888119B1 (en) | 2005-06-01 | 2011-03-09 | Maxygen, Inc. | Pegylated g-csf polypeptides and methods of producing same |
| DE102005033250A1 (de) | 2005-07-15 | 2007-01-18 | Bioceuticals Arzneimittel Ag | Verfahren zur Reinigung von G-CSF |
| WO2009139784A1 (en) * | 2008-05-13 | 2009-11-19 | Nora Therapeutics, Inc. | Human g-csf analogs and methods of making and using thereof |
| CN107412737A (zh) | 2010-01-19 | 2017-12-01 | 韩美科学株式会社 | 长效g‑csf缀合物的液体制剂 |
| US8980856B2 (en) | 2010-04-02 | 2015-03-17 | Curna, Inc. | Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3 |
| RU2467764C2 (ru) * | 2011-01-12 | 2012-11-27 | Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Пензенский институт усовершенствования врачей" Министерства здравоохранения и социального развития Российской Федерации | Способ лечения больных аутоиммунной хронической крапивницей с использованием внутривенного введения препарата "габриглобин" |
| WO2016013725A1 (ko) * | 2014-07-23 | 2016-01-28 | 주식회사 이큐스앤자루 | 과립구 콜로니 자극인자 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물 |
| KR101623906B1 (ko) | 2014-07-23 | 2016-05-24 | 주식회사 이큐스앤자루 | 과립구 콜로니 자극인자 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물 |
| JP2020506932A (ja) | 2017-02-03 | 2020-03-05 | ハンミ ファーマシューティカル カンパニー リミテッド | 持続性が増加した生理活性物質の結合体及びその用途 |
| US11684655B2 (en) | 2019-05-31 | 2023-06-27 | Spectrum Pharmaceuticals, Inc. | Methods of treating neutorpenia using G-CSF protein complex |
| US11267858B2 (en) | 2019-05-31 | 2022-03-08 | Spectrum Pharmaceuticals, Inc. | Methods of treatment using G-CSF protein complex |
| KR102375269B1 (ko) * | 2021-01-27 | 2022-03-17 | 한미약품 주식회사 | 단백질 액상 제제 및 이의 제조방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| AU7675487A (en) * | 1986-08-11 | 1988-05-19 | Cetus Corporation | Expression of granulocyte colony-stimulating factor |
| US5362853A (en) * | 1986-12-23 | 1994-11-08 | Kyowa Hakko Kogyo Co., Ltd. | Polypeptide derivatives of human granulocyte colony stimulating factor |
| US5714581A (en) * | 1986-12-23 | 1998-02-03 | Kyowa Hakko Kogyo Co., Ltd. | Polypeptide derivatives of human granulocyte colony stimulating factor |
| JPH02104598A (ja) | 1988-04-12 | 1990-04-17 | Kirin Amgen Inc | ヒト顆粒球コロニー刺激因子ポリペプチド誘導体 |
| NZ236819A (en) * | 1990-02-03 | 1993-07-27 | Max Planck Gesellschaft | Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions |
| GB9107846D0 (en) * | 1990-04-30 | 1991-05-29 | Ici Plc | Polypeptides |
| EP0626448A3 (de) * | 1993-05-26 | 1998-01-14 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Verfahren zur Herstellung und Reinigung von alpha-Interferon |
| US6476198B1 (en) * | 1993-07-13 | 2002-11-05 | The Scripps Research Institute | Multispecific and multivalent antigen-binding polypeptide molecules |
| US5451660A (en) * | 1993-12-13 | 1995-09-19 | Genentech, Inc. | Method for purifying polypeptides |
| WO1996013599A1 (en) * | 1994-11-01 | 1996-05-09 | Winfried Wels | Nucleic acid transfer system |
| US6100070A (en) * | 1995-10-05 | 2000-08-08 | G. D. Searle & Co. | G-CSF receptor agonists |
| KR100316347B1 (ko) * | 1998-09-15 | 2002-08-27 | 한미약품(주) | 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법 |
| IL152804A0 (en) * | 2000-05-16 | 2003-06-24 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
-
1999
- 1999-07-08 KR KR1019990027418A patent/KR100356140B1/ko not_active Expired - Lifetime
-
2000
- 2000-07-07 DE DE60021188T patent/DE60021188T3/de not_active Expired - Lifetime
- 2000-07-07 WO PCT/KR2000/000733 patent/WO2001004329A1/en not_active Ceased
- 2000-07-07 RU RU2002103159/13A patent/RU2232772C2/ru active
- 2000-07-07 AU AU57106/00A patent/AU757147C/en not_active Expired
- 2000-07-07 EP EP00942494A patent/EP1194575B2/en not_active Expired - Lifetime
- 2000-07-07 ES ES00942494T patent/ES2243275T5/es not_active Expired - Lifetime
- 2000-07-07 NZ NZ516476A patent/NZ516476A/en not_active IP Right Cessation
- 2000-07-07 CN CNB008100942A patent/CN1195859C/zh not_active Expired - Lifetime
- 2000-07-07 AT AT00942494T patent/ATE299187T1/de active
- 2000-07-07 CA CA2378543A patent/CA2378543C/en not_active Expired - Lifetime
- 2000-07-07 BR BR0012265-3A patent/BR0012265A/pt not_active IP Right Cessation
- 2000-07-07 BR BRPI0012265A patent/BRPI0012265B8/pt unknown
- 2000-07-07 PT PT00942494T patent/PT1194575E/pt unknown
- 2000-07-07 JP JP2001509533A patent/JP2003504069A/ja active Pending
- 2000-07-07 DK DK00942494T patent/DK1194575T4/da active
-
2002
- 2002-01-09 US US10/031,123 patent/US20040224393A1/en not_active Abandoned
-
2007
- 2007-10-19 US US11/975,541 patent/US7704709B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013540809A (ja) * | 2010-10-29 | 2013-11-07 | ハンミ サイエンス カンパニー リミテッド | 組み換え大腸菌からヒト顆粒球コロニー刺激因子を精製する方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1360636A (zh) | 2002-07-24 |
| CN1195859C (zh) | 2005-04-06 |
| DE60021188D1 (de) | 2005-08-11 |
| EP1194575B1 (en) | 2005-07-06 |
| EP1194575A1 (en) | 2002-04-10 |
| BRPI0012265B1 (pt) | 2018-11-21 |
| ES2243275T5 (es) | 2009-12-02 |
| DK1194575T3 (da) | 2005-10-17 |
| NZ516476A (en) | 2003-09-26 |
| EP1194575A4 (en) | 2002-10-24 |
| US20080064066A1 (en) | 2008-03-13 |
| ATE299187T1 (de) | 2005-07-15 |
| ES2243275T3 (es) | 2005-12-01 |
| DK1194575T4 (da) | 2009-12-07 |
| EP1194575B2 (en) | 2009-08-26 |
| US7704709B2 (en) | 2010-04-27 |
| DE60021188T3 (de) | 2010-04-01 |
| AU757147C (en) | 2005-03-03 |
| US20040224393A1 (en) | 2004-11-11 |
| KR100356140B1 (ko) | 2002-10-19 |
| AU5710600A (en) | 2001-01-30 |
| BRPI0012265B8 (pt) | 2021-05-25 |
| BR0012265A (pt) | 2002-03-12 |
| CA2378543A1 (en) | 2001-01-18 |
| RU2232772C2 (ru) | 2004-07-20 |
| CA2378543C (en) | 2010-05-18 |
| PT1194575E (pt) | 2005-10-31 |
| AU757147B2 (en) | 2003-02-06 |
| WO2001004329A1 (en) | 2001-01-18 |
| KR20010009171A (ko) | 2001-02-05 |
| DE60021188T2 (de) | 2006-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7704709B2 (en) | Modified human granulocyte-colony stimulating factor and process for producing same | |
| RU2198179C2 (ru) | Модифицированный сигнальный пептид энтеротоксина - ii e. coli и микроорганизм, экспрессирующий белок слияния упомянутого пептида с гетерологичным белком | |
| JP3730256B2 (ja) | 分泌シグナル遺伝子およびそれを有する発現ベクター | |
| EP0587427B1 (en) | Process for the production of human growth hormone | |
| JPH07502162A (ja) | 減システインｉｌ−６突然変異タンパク質 | |
| JPH0665318B2 (ja) | ヒト成長ホルモンの製造方法 | |
| JP3751883B2 (ja) | ヒトインターフェロンアルファの発現分泌ベクターおよびそれを用いたヒトインターフェロンアルファの生産方法 | |
| EP0276778A2 (en) | High level expression in E. coli of soluble mature hIL-1beta and derivatives with altered biological activity | |
| KR20030062854A (ko) | 분비형 벡터를 이용한 효모에서의 재조합 단백질의 제조방법 | |
| JP2535076B2 (ja) | シグナルペプチド、ｄｎａ配列、ベクタ―、細菌、およびポリペプチド周辺質生産法 | |
| JP3136356B2 (ja) | 改変型シグナルペプチドをコードするｄｎａ | |
| KR960016705B1 (ko) | 신규폴리펩티드 및 그것을 코우드하는 dna | |
| KR101364864B1 (ko) | 인간 적혈구 형성 자극인자 발현 벡터 및 이를 이용한 인간 적혈구 형성 자극인자의 생산방법 | |
| JP4524816B2 (ja) | Ｉｌ−６レセプター・ｉｌ−６直結融合蛋白質 | |
| JP2662044B2 (ja) | Ｄｎａ配列、発現ベクターおよびポリペプチドの周辺質生産方法 | |
| WO1988010302A1 (fr) | Nouveaux plasmides, cellules microbiennes, procede de preparation de polypeptides a action oncostatique et polypeptide secrete a action oncostatique | |
| Giga-Hama | Secretion of human interleukin-6 using the P-factor secretion signal in Schizosaccharomyces pombe | |
| RU2089612C1 (ru) | Рекомбинантная плазмидная днк purvgf, определяющая синтез фактора роста вируса осповакцины штамма л-ивп совместно с бета - галактозидазой escherichia coli, и штамм бактерий escherichia coli, содержащий рекомбинантную плазмидную днк purvgf - продуцент фактора роста вируса осповакцины штамма л-ивп | |
| KR100486070B1 (ko) | 인간 적혈구 형성 자극인자(ｅｐｏ) 발현 벡터 및 이를이용한 ｅｐｏ의 대량 생산방법 | |
| JPH0355111B2 (https=) | ||
| JPWO2000009718A1 (ja) | 真正ｍｋファミリータンパク質の大量分泌発現系 | |
| JPH0723788A (ja) | 神経栄養因子の生産方法及びそのためのべクター |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041019 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050119 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20050119 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050308 |